Combination Therapy of Pyrotinib and Metronomic Vinorelbine in HER2+ Advanced Breast Cancer after Trastuzumab Failure (PROVE): A Prospective Phase 2 Study
Cancer Research and Treatment · 15.04.2025 · 57 (2) · 434-442
DOI: 10.4143/crt.2024.340 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Cancer Research and Treatment, erschienen am 15.04.2025. Verfasst von Chunfang Hao und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Breast Oncology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China. Hauptthemen laut MEDLINE: Breast Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Vinorelbine, Acrylamides. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Purpose
Approximately 50%-74% of patients with metastatic human epidermal growth factor receptor 2 (HER2)–positive breast cancer do not respond to trastuzumab, with 75% of treated patients experiencing disease progression within a year. The combination of pyrotinib and capecitabine has showed efficacy in these patients. This study evaluates the efficacy and safety of pyrotinib combined with metronomic vinorelbine for trastuzumab-pretreated HER2-positive advanced breast cancer patients.Materials and Methods In this phase 2 trial, patients aged 18-75 years with HER2-positive advanced breast cancer who had previously failed trastuzumab treatment were enrolled to receive pyrotinib 400 mg daily in combination with vinorelbine 40mg thrice weekly. The primary endpoint was progression-free survival (PFS), while secondary endpoints included objective response rate (ORR), disease control rate (DCR), overall survival (OS), and safety.
Results
From October 21, 2019, to January 21, 2022, 36 patients were enrolled and received at least one dose of study treatment. At the cutoff date, 20 experienced disease progression or death. With a median follow-up duration of 35 months, the median PFS was 13.5 months (95% confidence interval [CI], 8.3 to 18.5). With all patients evaluated, an ORR of 38.9% (95% CI, 23.1 to 56.5) and a DCR of 83.3% (95% CI, 67.2 to 93.6) were achieved. The median OS was not reached. Grade 3 adverse events (AEs) were observed in 17 patients, with diarrhea being the most common (27.8%), followed by vomiting (8.3%) and stomachache (5.6%). There were no grade 4/5 AEs.
Conclusion
Pyrotinib combined with metronomic vinorelbine showed promising efficacy and an acceptable safety profile in HER2-positive advanced breast cancer patients after trastuzumab failure.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Breast Oncology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.
- National Clinical Research Center for Cancer, Tianjin, China.
- Department of Breast Oncology, Tianjin Cancer Hospital Airport Hospital, Tianjin, China.
Zitieren
APA
Hao, C., Wang, X., Shi, Y., Tong, Z., Li, S., Liu, X., Zhang, L., Zhang, J., Meng, W., & Zhang, L. (2025). Combination Therapy of Pyrotinib and Metronomic Vinorelbine in HER2+ Advanced Breast Cancer after Trastuzumab Failure (PROVE): A Prospective Phase 2 Study. Cancer Research and Treatment, 57(2), 434-442. https://doi.org/10.4143/crt.2024.340
Vancouver
Hao C, Wang X, Shi Y, Tong Z, Li S, Liu X, et al. Combination Therapy of Pyrotinib and Metronomic Vinorelbine in HER2+ Advanced Breast Cancer after Trastuzumab Failure (PROVE): A Prospective Phase 2 Study. Cancer Research and Treatment. 2025;57(2):434-442. doi:10.4143/crt.2024.340
BibTeX
@article{Hao2025,
author = {Hao, Chunfang and Wang, Xu and Shi, Yehui and Tong, Zhongsheng and Li, Shufen and Liu, Xiaodong and Zhang, Lan and Zhang, Jie and Meng, Wenjing and Zhang, Li},
title = {Combination Therapy of Pyrotinib and Metronomic Vinorelbine in HER2+ Advanced Breast Cancer after Trastuzumab Failure (PROVE): A Prospective Phase 2 Study},
journal = {Cancer Research and Treatment},
year = {2025},
volume = {57},
number = {2},
pages = {434--442},
doi = {10.4143/crt.2024.340}
}
EUVIMED